Inhibition of adjuvant-induced arthritis by 16 alpha-fluoro-5-androsten-17-one.

Abstract	The adrenal steroid dehydroepiandrosterone (DHEA) produces cancer-preventive, antiatherosclerotic, antidiabetic, immunomodulating, and anti-inflammatory effects in laboratory animals. The clinical use of DHEA is limited by its androgenicity. We have developed a synthetic congener of DHEA called fluasterone that, in animal tests, lacks the androgenicity, estrogenicity, and peroxisome-proliferating effects of DHEA but retains the cancer-preventive, antidiabetic, and anti-inflammatory efficacy. This report discusses how fluasterone ameliorates the development of joint inflammation in an adjuvant-arthritis model in Lewis rats.
Authors	Arthur G Schwartz, Laura L Pashko
Journal	Military medicine (Mil Med) Vol. 167 Issue 2 Suppl Pg. 60-3 (Feb 2002) ISSN: 0026-4075 [Print] England
PMID	11873519 (Publication Type: Journal Article)
Chemical References	Antineoplastic Agents Dehydroepiandrosterone 5-androstene-16-fluoro-17-one
Topics	Animals Antineoplastic Agents (pharmacology) Arthritis, Experimental (drug therapy) Dehydroepiandrosterone (analogs & derivatives, pharmacology) Female Rats Rats, Inbred Lew

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!